NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR)

Historical Holders from Q1 2014 to Q1 2025

Symbol
NKTR on Nasdaq
CUSIP
640268108
Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
186M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
133M
Holdings value
$124M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
144
Number of buys
61
Number of sells
-51
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.7% $8.52M 12.5M BlackRock, Inc. Mar 31, 2025
SAMLYN CAPITAL, LLC 5.2% $6.57M 9.67M Samlyn Capital, LLC Dec 31, 2024
EVENTIDE ASSET MANAGEMENT, LLC 3.61% $4.52M 6.65M Eventide Asset Management, LLC Dec 31, 2024
Deep Track Capital, LP 1.07% $1.34M 1.98M Deep Track Capital, LP Dec 31, 2024

Institutional Holders of NEKTAR THERAPEUTICS - Common Stock, $0.0001 par value (NKTR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 632K $430K -$61.2K $0.68 12
2024 Q4 133M $124M -$10.1M $0.93 144
2024 Q3 141M $183M +$5.56M $1.30 139
2024 Q2 135M $168M +$31.2M $1.24 132
2024 Q1 113M $105M -$4.22M $0.93 117
2023 Q4 119M $66.9M -$13.9M $0.57 116
2023 Q3 142M $84.6M +$3.89M $0.60 125
2023 Q2 136M $78.1M -$21.6M $0.58 133
2023 Q1 171M $120M -$6.89M $0.70 183
2022 Q4 169M $381M -$28.1M $2.26 204
2022 Q3 172M $549M -$30.5M $3.20 201
2022 Q2 181M $687M +$15.7M $3.80 200
2022 Q1 175M $945M -$13.6M $5.39 210
2021 Q4 167M $2.26B +$159M $13.51 223
2021 Q3 167M $3.01B -$14.8M $17.96 225
2021 Q2 168M $2.88B -$33.5M $17.16 228
2021 Q1 169M $3.39B -$52.2M $20.00 223
2020 Q4 172M $2.92B -$16.1M $17.00 222
2020 Q3 175M $2.91B -$42.1M $16.59 231
2020 Q2 175M $4.05B -$45.3M $23.16 244
2020 Q1 177M $3.16B +$47.4M $17.85 225
2019 Q4 175M $3.78B -$41.5M $21.59 265
2019 Q3 178M $3.24B +$141M $18.22 268
2019 Q2 164M $5.84B +$925M $35.58 321
2019 Q1 160M $5.39B -$79.6M $33.60 332
2018 Q4 163M $5.36B +$29.6M $32.87 317
2018 Q3 158M $9.65B -$32.3M $60.96 372
2018 Q2 160M $7.83B -$68.2M $48.83 363
2018 Q1 157M $16.7B +$336M $106.26 346
2017 Q4 154M $9.21B +$141M $59.72 258
2017 Q3 154M $3.69B +$66.2M $24.00 202
2017 Q2 151M $2.95B +$97.2M $19.55 195
2017 Q1 146M $3.43B +$472M $23.47 198
2016 Q4 145M $1.78B +$106M $12.27 193
2016 Q3 134M $2.29B -$2.55M $17.18 189
2016 Q2 134M $1.91B -$65.6M $14.23 171
2016 Q1 139M $1.91B -$10.6M $13.75 170
2015 Q4 139M $2.35B -$21.1M $16.85 176
2015 Q3 140M $1.54B +$32.3M $10.96 161
2015 Q2 137M $1.71B +$153M $12.51 178
2015 Q1 126M $1.38B +$60M $11.00 150
2014 Q4 120M $1.86B +$32.2M $15.50 162
2014 Q3 118M $1.43B +$50.4M $12.07 144
2014 Q2 114M $1.46B -$20.6M $12.82 140
2014 Q1 115M $1.4B +$164M $12.12 139